PLRX earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -0.60. Updated 2026-07-23.
Pliant Therapeutics (PLRX) Research Hub
Pliant Therapeutics (PLRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.17 USD (+1.74%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.60, market cap 0.07B. This hub links to the full technical, earnings and options research available for PLRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.17 USD (+1.74%) |
| 52-week range | 1.03 USD – 1.2 USD |
| Trend regime | Range |
| 14-day RSI | 65 (Bullish) |
| Trailing P/E | -0.60 |
| Market cap | 0.07B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for PLRX
Covered Call on PLRX: how it works, illustrative setup around the real 1.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PLRX: how it works, illustrative setup around the real 1.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PLRX: how it works, illustrative setup around the real 1.17 USD price, max profit/loss, breakeven and when to use it. Educational.
PLRX technical analysis: range, last 1.17 USD, RSI 65, 52w range 1.03 USD–1.2 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PLRX in?
Pliant Therapeutics (PLRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PLRX in an uptrend or downtrend?
As of 2026-09-11, PLRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PLRX's trailing P/E ratio?
PLRX's trailing P/E is -0.60, with a market cap of 0.07B. See the earnings research page for full valuation detail.
When does PLRX next report earnings?
PLRX is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.33 USD.